Navigation Links
PharmAthene Reports First Quarter 2011 Financial and Operating Results
Date:5/11/2011

ed; 46,322,026 and 46,238,244 shares issued and outstanding at March 31, 2011 and December 31, 2010, respectively4,6324,624Additional paid-in-capital201,570,845200,847,468Accumulated other comprehensive income1,227,4341,250,497Accumulated deficit(191,967,541)(189,891,884)Total stockholders'  equity10,835,37012,210,705Total liabilities and stockholders' equity

$

23,875,074$

27,199,045PHARMATHENE, INC.UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONSThree months ended March 31,20112010Revenue

$

6,337,722$

3,116,553Operating expenses:Research and development5,820,3744,952,393General and administrative4,939,6545,325,422Depreciation and amortization117,629245,258Total operating expenses10,877,65710,523,073Loss from operations(4,539,935)(7,406,520)Other income (expense):Interest income3,1543,483Interest expense(15,435)(948,150)Other income (expense)(11,906)139,422Change in market value of derivative instruments2,488,465267,496Total other income (expense)2,464,278(537,749)Net loss

$

(2,075,657)$

(7,944,269)Basic and diluted net loss per share

$

(0.04)$

(0.28)Weighted average shares used in calculation of basic and diluted net loss per share46,276,87428,172,802
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
2. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
3. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
4. PharmAthene Reports Third Quarter 2010 Financial and Operational Results
5. PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000
6. PharmAthene Announces Pricing of $15 Million Public Offering
7. PharmAthene Announces Proposed Common Stock Offering
8. PharmAthene Announces $3.9 Million Registered Direct Offering
9. PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
10. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
11. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 On ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique project ... project BIOCAD develops a number of innovative drugs based ... diseases. The ceremony took place at the International Exhibition ...
(Date:7/10/2014)... 2014 /PRNewswire-iReach/ -- Tute Genomics, the leader ... an agreement with Lineagen, Inc., to provide ... Dx PLUS.  Lineagen, focused on the ... currently offers FirstStep Dx PLUS, a ... by healthcare providers as a first-line genetic ...
(Date:7/10/2014)... THOUSAND OAKS, Calif., July 10, 2014   Ceres, ... biotechnology and seed company, announced today financial results for ... an update on its business. Ceres reported ... progress in product performance this growing season in Brazil, ... that affected the company,s sorghum evaluation areas for part ...
(Date:7/10/2014)... Adelaide research may help in the fight against terrorism ... tiny quantities of explosives with the use of light ... Sensors and Actuators B: Chemical , the researchers ... explosives in concentrations as low as 6.3 ppm (parts ... a few minutes. , "Traditionally explosives detection has involved ...
Breaking Biology Technology:Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Detecting trace amounts of explosives with light 2
... oncology intelligence initiative powered by The Arcas Group, announced ... following this month,s annual meeting of the American Society ... expand on previous Quick Polls carried out after the ... efforts after the American Society of Hematology (ASH) annual ...
... Incorporated (NASDAQ: SPEX ) -- an ... syndrome and atherosclerosis, and providers of technical and ... pharmaceutical companies -- today announced that its Annual ... will be held on Tuesday, November 15, 2011, ...
... 2011 ,   ... that its,US-subsidiary NextGen Sciences Inc, a leader in ... cerebrospinal,fluid (CSF) multiple protein (multiplex) assay, csf ... qualification . The assay simultaneously measures,43 human CSF ...
Cached Biology Technology:MDOUTLOOK® 4th Annual Quick Polls From ASCO 2011: Report on Clinical Impact of New Developments in Cancer Therapeutics 2MDOUTLOOK® 4th Annual Quick Polls From ASCO 2011: Report on Clinical Impact of New Developments in Cancer Therapeutics 3Spherix Announces Annual Shareholders Meeting Date 2NextGen Sciences Launches Multiple Protein cerebrospinal fluid (CSF) CNS Disease Biomarker Assay 2NextGen Sciences Launches Multiple Protein cerebrospinal fluid (CSF) CNS Disease Biomarker Assay 3
(Date:7/11/2014)... is evidence that under the normal circumstances, ... development, maintain neuronal environment, and exhibit therapeutic ... neurodegenerative disease. Previous studies have found that ... after chemical induction have reduced viability, which ... Prof. Xiaodong Yuan, Kailuan General Hospital, Hebei ...
(Date:7/10/2014)... Fe, Albuquerque, and other major cities in New Mexico, ... treated municipal wastewater rather than precious potable water supplies. ... 40% of all golf courses receive treated effluent. Reusing ... , Additionally, golf courses and homeowners alike fertilize their ... fertilizer is nitrate. A New Mexico State University turfgrass ...
(Date:7/10/2014)... 2014  Unisys Corporation,s (NYSE: UIS ) subsidiary ... today announced that it has been selected by the Dutch ... new Basic Provision Biometrics solution for penitentiaries across ... contract with a solution based on its open standards-based ... the contract is up to seven years, with the new ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3
... in the online edition of Physiological Genomics finds that individuals ... The study offers the first evidence of the role that ... controls sugar entry into the cells has on sugar ... in sugar. The study was conducted by Ahmed ...
... to Critical Data with MobileCop(R) ... ... International Inc.,(OTC Bulletin Board: BKYI), a leader in finger-based biometric,identification and ... Baltimore (MD) Police Department ("BPD"),for additional licenses of BIO-key,s MobileCop software ...
... new ways to stop the progression of cancer, researchers ... discovered a compound that has shown to prevent cancer ... Gene Regulation and Systems Biology. The compound, which ... normal cells from turning into cancer cells and inhibited ...
Cached Biology News:Genetic variation linked to sugary food 2Genetic variation linked to sugary food 3BIO-key(R) Receives $335,000 Contract Award From Baltimore Police 2BIO-key(R) Receives $335,000 Contract Award From Baltimore Police 3Chemical compound prevents cancer in lab 2
... GeneBLAzer cell-based assays utilize the ... of the negatively charged fluorescent beta-lactamase ... esters readily enter the cell, where ... converts them into their negatively charged ...
Src cDNA Expression Kit (wild type)...
1M stock solution (238mg/ml)...
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
Biology Products: